RANK Ligand-targeted Therapy: A Novel Approach to Prevent Bone Loss and Fractures in Men with Prostate Cancer  Matthew R. Smith  European Urology Supplements  Volume 8, Issue 11, Pages 834-838 (November 2009) DOI: 10.1016/j.eursup.2009.08.006 Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 1 Time to first fracture in men with nonmetastatic prostate cancer receiving gonadotropin-releasing hormone (GnRH) agonists compared with controls. Redrawn with permission from the American Society of Clinical Oncology [8]. European Urology Supplements 2009 8, 834-838DOI: (10.1016/j.eursup.2009.08.006) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 2 Effect of denosumab (60mg every 6 mo) on (a) total hip and (b) femoral neck bone mineral density in men receiving androgen-deprivation therapy compared with placebo. Values are mean plus or minus 95% confidence interval. Adapted with permission from the Massachusetts Medical Society [22]. European Urology Supplements 2009 8, 834-838DOI: (10.1016/j.eursup.2009.08.006) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 3 Incidence of new vertebral fractures during 3 yr of treatment with denosumab or placebo in men receiving androgen-deprivation therapy. Adapted with permission from the Massachusetts Medical Society [22]. RR=relative risk. European Urology Supplements 2009 8, 834-838DOI: (10.1016/j.eursup.2009.08.006) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 4 Design of an ongoing study assessing the ability of denosumab to improve bone metastases–free survival in men receiving androgen-deprivation therapy. s.c.=subcutaneous; Q4W=every 4 wk. European Urology Supplements 2009 8, 834-838DOI: (10.1016/j.eursup.2009.08.006) Copyright © 2009 European Association of Urology Terms and Conditions

Fig. 5 Ongoing investigations may show benefits of denosumab at various points in the progression of prostate cancer. PSA=prostate-specific antigen; SRE=skeletal-related event; ADT=androgen-deprivation therapy; HRPC=hormone-refractory prostate cancer. European Urology Supplements 2009 8, 834-838DOI: (10.1016/j.eursup.2009.08.006) Copyright © 2009 European Association of Urology Terms and Conditions